Teva Pharmaceutical Industries reported a quarterly EPS of $0.70, surpassing estimates by $0.01, with a return on equity of 42.46% and a negative net margin of 9.91%. Director Roberto Mignone sold 286,000 shares, reducing his stake by 29.15%. Analysts project an EPS of 2.5 for the fiscal year, with a consensus rating of "Moderate Buy" and an average price target of $23.43.